Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: Very Short-course vs Standard Course Antibiotics for Acute Cholangitis
NCT05750966Completed
- Sponsor
- University of Amsterdam
- Start
- Jul 2023
- Primary completion
- Apr 2026
- Modality
- Reversible Covalent Inhibitors, Nanoparticles, Transdermal Patches
- Countries
- 1
01
Overview
Randomised trial in cholangitis (2 arms), sponsored by University of Amsterdam. Primary endpoint: Clinical cure rate without relapse at 30 days. Started Jul 2023; status: completed.
02
Conditions
cholangitis
Beyond the preview
Go deeper on NCT05750966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750966.